Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-06-05
2007-06-05
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
10379154
ABSTRACT:
The present invention provides compositions for oral administration of compounds having A2Aadenosine receptor agonist activity. These compositions are useful for treatment of inflammatory conditions.
REFERENCES:
patent: 3892777 (1975-07-01), Gruenman et al.
patent: 4012495 (1977-03-01), Schmeichen et al.
patent: 4193926 (1980-03-01), Schmiechen et al.
patent: 4242345 (1980-12-01), Brenner et al.
patent: 4665074 (1987-05-01), Amschler
patent: 4824660 (1989-04-01), Angello et al.
patent: 4879296 (1989-11-01), Daluge et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4956345 (1990-09-01), Miyasaka et al.
patent: 4965271 (1990-10-01), Mandell et al.
patent: 5070877 (1991-12-01), Mohiuddin et al.
patent: 5096906 (1992-03-01), Mandell et al.
patent: 5124455 (1992-06-01), Lombardo et al.
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5189027 (1993-02-01), Miyashita et al.
patent: 5272153 (1993-12-01), Mandell et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5298508 (1994-03-01), Jacobson et al.
patent: 5565462 (1996-10-01), Eitan et al.
patent: 5593975 (1997-01-01), Cristalli
patent: 5593976 (1997-01-01), Mongelli et al.
patent: 5665754 (1997-09-01), Feldman et al.
patent: 5668139 (1997-09-01), Belardinelli et al.
patent: 5696254 (1997-12-01), Mansour et al.
patent: 5731296 (1998-03-01), Sollevi
patent: 5756706 (1998-05-01), Mansour et al.
patent: 5854081 (1998-12-01), Linden et al.
patent: 5877180 (1999-03-01), Linden et al.
patent: 5932558 (1999-08-01), Cronstein et al.
patent: 5998386 (1999-12-01), Feldman
patent: 6004945 (1999-12-01), Fukunaga
patent: RE36494 (2000-01-01), Olsson et al.
patent: 6020321 (2000-02-01), Cronstein et al.
patent: 6020339 (2000-02-01), Perrier et al.
patent: 6034089 (2000-03-01), Han et al.
patent: 6060481 (2000-05-01), LaNoue et al.
patent: 6117878 (2000-09-01), Linden et al.
patent: 6303619 (2001-10-01), Linden et al.
patent: 6322771 (2001-11-01), Linden et al.
patent: 6332771 (2001-12-01), Adams et al.
patent: 6339072 (2002-01-01), Martin et al.
patent: 6387889 (2002-05-01), Endo et al.
patent: 6448235 (2002-09-01), Linden et al.
patent: 6514949 (2003-02-01), Linden et al.
patent: 6525032 (2003-02-01), Mantell et al.
patent: 6531457 (2003-03-01), Linden et al.
patent: 6545002 (2003-04-01), Linden et al.
patent: 6624158 (2003-09-01), Mantell et al.
patent: 6670334 (2003-12-01), Linden
patent: 2002/0032168 (2002-03-01), Mantrell et al.
patent: 2002/0058641 (2002-05-01), Mantell et al.
patent: 2003/0013675 (2003-01-01), Yeadon et al.
patent: 2005/0282831 (2005-12-01), Beauglehole et al.
patent: 2006/0100169 (2006-05-01), Rieger et al.
patent: 488336 (1995-05-01), None
patent: 0700908 (1996-03-01), None
patent: 1150991 (2004-04-01), None
patent: HU174074 (1979-10-01), None
patent: WO-95/11681 (1995-05-01), None
patent: WO-96/02553 (1996-02-01), None
patent: WO-9604280 (1996-02-01), None
patent: WO-9847509 (1998-10-01), None
patent: WO-98/57651 (1998-12-01), None
patent: WO-99/34804 (1999-07-01), None
patent: WO-99/38877 (1999-08-01), None
patent: WO-99/41267 (1999-08-01), None
patent: WO-99/62518 (1999-12-01), None
patent: WO-99/63938 (1999-12-01), None
patent: WO-99/67263 (1999-12-01), None
patent: WO-99/67264 (1999-12-01), None
patent: WO-99/67265 (1999-12-01), None
patent: WO-99/67266 (1999-12-01), None
patent: WO-00/44763 (2000-01-01), None
patent: WO-00/23457 (2000-04-01), None
patent: WO-00/78774 (2000-12-01), None
patent: WO-02/09701 (2002-02-01), None
patent: WO-02/096462 (2002-12-01), None
patent: WO-03/014137 (2003-02-01), None
Ross et al., Journal of Heart and Lung Transplantation, (Jan. 1999) vol. 18, No. 1, p. 72.
Abiru, T., et al. ,“Nucleosides and Nucleotides. 107. 2-(Cycloalkylalkynyl)adenosines: Adenosine A2 Receptor Agonists with Potent Antihypertensive Effects”,Journal of Medicinal Chemistry, 35, (1992),pp. 2253-2260.
Ali, H., et al. ,“Methylxanthines Block Antigen-induced Responses in RBL-2H3 Cells Independently of Adenosine Receptors or Cyclic AMP: Evidence for Inhibition of Antigen Binding to IgE”,Journal of Pharmacology and Experimental Therapeutics, 258, (1991),pp. 954-962.
Andersson, P.,et al., “Anti-anaphylactic and anti-inflammatory effects of xanthines in the lung”,Curr. Clin. Pract. Ser., (1985),pp. 187-192.
Baraldi, Pier.G.,“Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)arlkynyl-6-0arylcarbamoyl, and N6-Carboxamido derivatives of adenosine-5′-N-ethyluronamide as A1 and A3 Adenosine receptor agonists”,J. Med. Chem., vol. 41, No. 17, XP002149470, (1998),3174-3185.
Berkich, D., et al.,“Evidence of Regulated Coupling of A1 Adenosine Receptors by Phosphorylation in Zucker Rats.”,American Journal of Physiology, 268 (4), (Apr. 1995),pp. E693-E704.
Bhattacharya, S.,et al.,“Effects of Long-term Treatment With the Allosteric Enhancer, PD81,723, on Chinese Hamster Ovary Cells Expressing Recombitant Human A1 Adenosine Receptors”,Molecular Pharmacology, 50 (1), (Jul. 1996),pp. 104-111.
Bhattacharya, S.,et al.,“The Allosteric Enhancer, PD 81,723, Stabilizes Human A1 Adenosine Receptor Coupling to G Proteins”,Biochimica et Biophysica Acta, 1265 (1), (Feb. 1995),pp. 15-21.
Bridges, A.J.,“N6-[2-(3,5-Dimethoxyphenyl)-2-(2-Methylphenyl)-Ethyl]Adenosine and Its Uronamide Derivatives. Novel Adenosine Agonists With Both High Affinity and High Selectivity for the Adenosine A2 Receptor”,Journal of Medicinal Chemistry, 31 (7), (1988),pp. 1282-1285.
Bruns, R.,“Adenosine Receptors—Roles and Pharmacology”,Biological Actions of Extracellular ATP, 603, Annals of The New York Academy of Sciences,(1990),pp. 211-226.
Bruns, R.F.,et al. ,“Characterization of the A2 Adenosine Receptor Labeled by [3H]NECA in Rat Striatal Membranes”,Molecular Pharmacology, 29, (1986),pp. 331-346.
Buster, B., et al.,“The Effect of Adenosine Receptor Agonists on Neutrophil Pleocytosis and Blood-Brain Barrier Pathophysiology in Experimental Bacterial Meningitis”,Abstract of the Interscience Conference on Antimicrobial Agents and Chemotherapy, 37, Abstract No. B-72,(1997),p. 39.
Carruthers, A.M., et al. ,“Hypotensive Responses to the Putative Adenosine A3 Receptor Agonist N6-20(4-Aminophenyl)-Ethyladenosine in the Rat”,Drug Development Research, 30, (1993),pp. 147-152.
Cembrzynska-Nowak, M.,et al.,“Elevated Release of Tumor Necrosis Factor-alpha and Interferon-gamma by Bronchoalveolar Leukocytes From Patients With Bronchial Asthma.”,American Review of Respiratory Disease, 147(2), (1993),291-295.
Cothran, D.L.,et al ,“Ontogeny of Rat Myocardial A1 Adenosine Receptors”,Biol Neonate, 68 (2), (1995),pp. 111-118.
Cristalli, G.,“2-Alkynyl Derivatives of Adenosine an Adenosine-5′-N-ethyluronamide as Selective Agonists at A2 Adenosine Receptors”,Journal of Medicinal Chemistry, 35 (13), (1992),pp. 2363-2368.
Cronstein, B.N. ,“Adenosine Modulates the Generation of Superoxide Anion by Stimulated Human Neutrophils Via Interaction With a Specific Cell Surface Receptor”,Annals New York Academy of Science, 451, (1985),291-314.
Cronstein, B.N.,“Adenosine; A Physiologic Modulator Of Superoxide Anion Generated By Human Neutrophils. Adenosine Acts Via An A2 Receptor On Human Neutrophils”,Journal Of Immunology, 135 (2), (1985),pp. 1366-1371.
Cronstein, B.N.,“Engagement of Adenosine Receptor Inhibits Hydrogen Peroxide (H202) Release by Activated Human Neutrophils”,Clinical Immunology and Immunopathology, 42(1), (1987),76-85.
Cronstein, B.N.,“Methotrexate Inhibits Leukocyte Influx Into Inflammatory Sites Via The Adenosine (A2) Receptor”,Clinical Research, 41 (2), (1993),p. 244A.
Cronstein, N.,et al.,“Occupancy Of Adenosine Receptors Raises Cyclic AMP Alone And In Synergy With Occupancy Of Chemoattractant Receptors And Inhibits Membrane Depolarization”,Biochemical Journal, 252 (3), (1988),pp. 709-715.
Cronstein, B.N.,“The Adenosine/Neutrophil Parado
Kron Irving L.
Linden Joel M.
MacDonald Timothy
Okusa Mark
Sarembock Ian J.
Schwegman Lundberg Woessner and Kluth
Spivack Phyllis G.
University of Virginia Patent Foundation
LandOfFree
Pharmaceutical compositions having A 2A adenosine receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions having A 2A adenosine receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions having A 2A adenosine receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3857014